Deguchi T, Kuriyama M, Shinoda I, Okano M, Ban Y, Matsui H, Yamada A, Saito I, Kawada Y
Department of Urology, Gifu University School of Medicine, Japan.
Urol Res. 1991;19(1):25-30. doi: 10.1007/BF00294017.
Prostate-specific antigen (PA) and gamma-seminoprotein (gamma-Sm) were compared by immunocytochemical, immunodiffusion and immunoblotting methods using rabbit anti-PA antibody and rabbit anti-gamma-Sm antibody. Enzyme immunoassays (EIAs) were developed for measurements of PA and gamma-Sm to determine a correlation between serum PA and gamma-Sm levels in patients with prostate cancer. The patterns of localization and distribution of PA and gamma-Sm were identical in prostate tissue sections, including benign and cancerous human prostates. The immunodiffusion study showed that the antigens with which anti-PA antibody and anti-gamma-Sm antibody reacted in seminal plasma and prostate tissue homogenates were identical to each other. In the immunoblotting study, anti-PA antibody and anti-gamma-Sm antibody recognized a single antigen corresponding to a molecular weight of approximately 33,000 both in seminal plasma and prostate tissue homogenates. The EIAs developed in this study were sensitive, specific, and reproducible, and the correlation between serum PA and gamma-Sm values determined by these EIAs was highly significant (r = 0.99, P less than 0.001). These results indicated that PA and gamma-Sm were immunologically identical and that serum PA and gamma-Sm determined by immunoassays using anti-PA antibody and anti-gamma-Sm antibody should be evaluated as identical tumor markers for serodiagnosis of prostate cancer.
使用兔抗前列腺特异性抗原(PA)抗体和兔抗γ-精浆蛋白(γ-Sm)抗体,通过免疫细胞化学、免疫扩散和免疫印迹法对PA和γ-Sm进行了比较。开发了酶免疫测定法(EIA)用于测量PA和γ-Sm,以确定前列腺癌患者血清PA和γ-Sm水平之间的相关性。PA和γ-Sm在前列腺组织切片(包括良性和癌性人类前列腺)中的定位和分布模式相同。免疫扩散研究表明,抗PA抗体和抗γ-Sm抗体在精浆和前列腺组织匀浆中与之反应的抗原彼此相同。在免疫印迹研究中,抗PA抗体和抗γ-Sm抗体在精浆和前列腺组织匀浆中均识别出一种分子量约为33,000的单一抗原。本研究开发的EIA灵敏、特异且可重复,通过这些EIA测定的血清PA和γ-Sm值之间的相关性非常显著(r = 0.99,P < 0.001)。这些结果表明,PA和γ-Sm在免疫学上是相同的,并且使用抗PA抗体和抗γ-Sm抗体通过免疫测定法测定的血清PA和γ-Sm应作为前列腺癌血清学诊断的相同肿瘤标志物进行评估。